Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

CC-486 Mechanism Imparted By Extended Exposure of Azacitidine Upregulates Myeloid Differentiation Markers and Induces Cell Death in AML Cells

Diana R. Dunshee, Yumin Dai, Jessica C. Jang, Alberto Risueño, Danny V Jeyaraju, Patrick Hagner, PhD, Wendy L. See, Kyle MacBeth, Xiaomin Wang, Ignazia La Torre, Barry Skikne, MD, C.L. Beach, PharmD, Keshava Kumar, PhD, Anjan Thakurta, Daniel Lopes de Menezes, PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-137606

Published: 2020

Journal Articles

Comparative Efficacy of CC-486 Versus Injectable Azacitidine (AZA) in Patients (Pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy: Findings from an Indirect Treatment Comparison (ITC)

Clara Chen, Tim Disher, Muhaimen Siddiqui, Ignazia La Torre, Barry Skikne, MD, Beatrice Suero, Heather Cameron, Roya Gavanji, Chris Cameron

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-136625

Published: 2020

Journal Articles

CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial

Esther Natalie Oliva, MD, Suman Kambhampati, MD, Albert Oriol, Ignazia La Torre, Barry Skikne, MD, C.L. Beach, PharmD, Keshava Kumar, PhD, Qian Dong, DrPH, Clara Chen, Sandip Ranjan, MTech, Zephirin Kiendrebeogo, Msc, PMP, Thorsten Braun, MD PhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137562

Published: 2020

Journal Articles

CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

Gail J. Roboz, MD, Farhad Ravandi, MBBS, Andrew H Wei, MBBS, PhD, Hervé Dombret, MD, Hartmut Döhner, Felicitas Thol, Maria Teresa Voso, MD, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Alberto Risueño, Daniel Lopes de Menezes, PhD, Gert Ossenkoppele, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-140837

Published: 2020

Journal Articles

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

Farhad Ravandi, MBBS, Christopher Pocock, MBBS, Dominik Selleslag, MD, Pau Montesinos, MD PhD, Hamid Sayar, MD MSc, Maurizio Musso, MD, Angela Figuera Alvarez, Hana Safah, MD, William Tse, MD FACP, Sang Kyun Sohn, MDPhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Timothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Hervé Dombret, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-137669

Published: 2020

Journal Articles

CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

Andrew Wei, MBBS,PhD, Gail J. Roboz, MD, Hervé Dombret, MD, Hartmut Döhner, Andre C. Schuh, Pau Montesinos, MD PhD, Christopher Pocock, MBBS, Dominik Selleslag, MD, Sergey N. Bondarenko, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Farhad Ravandi, MBBS

Blood (2020) 136 (Supplement 1): 38–40.

https://doi.org/10.1182/blood-2020-138498

Published: 2020

Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Blood (2019) 134 (Supplement_2): LBA-3.

https://doi.org/10.1182/blood-2019-132405

Published: 2019

Journal Articles

Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)

Antonio Almeida, MD PhD, Valeria Santini, MD, Stefanie Gröpper, MD, Anna Jonasova, MD, Norbert Vey, Aristoteles Giagounidis, MD PhD, Eva Hellström-Lindberg, MD PhD, Ghulam J. Mufti, MD PhD, Guillermo Sanz, MD PhD, Barry Skikne, MD, Albert Hoenekopp, MD, Francis Séguy, Jianhua Zhong, PhD, Pierre Fenaux, MD PhD

Blood (2015) 126 (23): 2880.

https://doi.org/10.1182/blood.V126.23.2880.2880

Published: 2015

Journal Articles

CC-486 (Oral Azacitidine) Monotherapy in Patients with Acute Myeloid Leukemia (AML)

Michael R. Savona, MD, Steven D. Gore, MD, Kathryn S. Kolibaba, Stacey M. Ukrainskyj, BSN, Keshava Kumar, PhD, Qian Dong, MS, Joel Hetzer, PhD, Barry Skikne, MD, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 452.

https://doi.org/10.1182/blood.V126.23.452.452

Published: 2015

Journal Articles

Prevalence and Clinical Impact of Additional Cytogenetic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Deletion 5q from the MDS-003 and MDS-004 Studies

Aristoteles Giagounidis, MD PhD, Alan F. List, MD, Eva Hellstrom-Lindberg, MD PhD, Ghulam J. Mufti, MD PhD, Brigitte Schlegelberger, MD PhD, John Morrill, Chengqing Wu, PhD, Barry Skikne, MD, Pierre Fenaux, MD PhD, Gudrun Göhring, MD

Blood (2014) 124 (21): 3270.

https://doi.org/10.1182/blood.V124.21.3270.3270

Published: 2014

Journal Articles

Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML)

Steven D. Gore, MD, Christopher R. Cogle, MD, Barry Skikne, MD, Eric Laille, MS, Tao Shi, PhD, Kyle J. MacBeth, PhD, Heidi Giordano, MA, MBA, Guillermo Garcia-Manero

Blood (2011) 118 (21): 1546.

https://doi.org/10.1182/blood.V118.21.1546.1546

Published: 2011

Journal Articles

Outcomes for Patients (Pts) with Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) with del5q Aged < 65 Years Treated with Lenalidomide (LEN) in MDS-003 and MDS-004: A Retrospective Combined Analysis

Pierre Fenaux, MD, PhD, Aristoteles Giagounidis, MD, Alan F. List, MD, Stephen D. Nimer, MD, Eva Hellström-Lindberg, Bayard L. Powell, MD, Xujie Yu, PhD, Barry Skikne, MD, Jamile M. Shammo, MD, Consuelo del Cañizo, MD

Blood (2011) 118 (21): 1723.

https://doi.org/10.1182/blood.V118.21.1723.1723

Published: 2011

Journal Articles

Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen.

Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Steven D. Gore, MD, Valeria Santini, MD, Pierre Fenaux, MD, PhD, Lewis R. Silverman, MD, Anne Hagemeijer, MD, Barry Skikne, MD, Eva Hellstrom-Lindberg, MD, PhD, John F. Seymour, MBBS, PhD, FRACP, CL Beach, PharmD, Jay Backstrom, MD, MPH, Indrasiri Fernando, PhD

Blood (2009) 114 (22): 1755.

https://doi.org/10.1182/blood.V114.22.1755.1755

Published: 2009

Journal Articles

Pegylated Liposomal Doxorubicin (PLD), Dexamethasone and Low Dose Thalidomide (DDt): An Active Regimen in the Frontline Therapy for Multiple Myeloma (MM).

Delva Deauna-Limayo, MD, Suman Kambhampathi, MD, David Bodensteiner, MD, Siddharta Ganguly, MD, Barry Skikne, MD, Karen Wolfe, Holly Smith, Ron Krebill, Dean Merkel, Da Zhang, MD, Carol Blecke, Sarah Spencer, Matthew Mayo

Blood (2007) 110 (11): 3619.

https://doi.org/10.1182/blood.V110.11.3619.3619

Published: 2007

NARROW

CC-486 Mechanism Imparted By Extended Exposure of Azacitidine Upregulates Myeloid Differentiation Markers and Induces Cell Death in AML Cells

Comparative Efficacy of CC-486 Versus Injectable Azacitidine (AZA) in Patients (Pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy: Findings from an Indirect Treatment Comparison (ITC)

CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial

CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)

CC-486 (Oral Azacitidine) Monotherapy in Patients with Acute Myeloid Leukemia (AML)

Prevalence and Clinical Impact of Additional Cytogenetic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Deletion 5q from the MDS-003 and MDS-004 Studies

Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML)

Outcomes for Patients (Pts) with Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) with del5q Aged < 65 Years Treated with Lenalidomide (LEN) in MDS-003 and MDS-004: A Retrospective Combined Analysis

Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen.

Pegylated Liposomal Doxorubicin (PLD), Dexamethasone and Low Dose Thalidomide (DDt): An Active Regimen in the Frontline Therapy for Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only